---
title: 'Industry Daily Summary: What Happened on October 30, 2026'
headline: Lilly raises 2026 outlook as Mounjaro and Zepbound sales climb
description: The two drugs generated about $16.1 billion in third-quarter sales. AstraZeneca
  is seeking $1.5 billion in annual savings by 2029.
url: https://thebench.bio/news/industry/2026-10-30
topic: industry
date: '2026-10-30'
covers:
- '2026-10-30'
date_published: '2026-10-30T12:04:31Z'
date_modified: '2026-10-30T12:04:31Z'
tags:
- Industry
sources: 2
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on October 30, 2026

**Lilly raises 2026 outlook as Mounjaro and Zepbound sales climb**

The two drugs generated about $16.1 billion in third-quarter sales. AstraZeneca is seeking $1.5 billion in annual savings by 2029.

## Today in brief

Eli Lilly raised its 2026 revenue outlook to $91 billion to $92 billion as Mounjaro and Zepbound sales increased 65% and 59%, respectively. [1]

## Lilly lifts outlook after 39% revenue growth

Eli Lilly’s third-quarter revenue rose 39% from a year earlier, prompting the company to raise its 2026 outlook to $91 billion to $92 billion from $85 billion to $87 billion. [1] Mounjaro generated $10.7 billion in global sales and Zepbound $5.4 billion, for about $16.1 billion combined. [1] Revenue growth slowed from 48% in the second quarter, with pricing pressure cited as a factor. [1]

## Also worth knowing

- AstraZeneca is seeking $1.5 billion in annual savings by the end of 2029. [2]

## The day in numbers

- **39%**: Lilly’s third-quarter revenue growth compared with the same quarter in 2025. [1]
- **About $16.1 billion**: Combined third-quarter global sales of Mounjaro and Zepbound. [1]
- **$91 billion to $92 billion**: Lilly’s revised 2026 revenue outlook, raised from $85 billion to $87 billion. [1]

## Also published

- [Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game](<https://www.biopharmadive.com/news/biopharma-earnings-q3-2026-lilly-novartis-gsk/873167/>), BioPharma Dive
- [Sanofi eyeing pipeline deals ahead of Dupixent patent loss](<https://pharmaphorum.com/news/sanofi-eyeing-pipeline-deals-ahead-dupixent-patent-loss>), pharmaphorum
- [Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)](<https://www.labiotech.eu/podcast/genprex-bets-on-a-one-time-gene-therapy-for-diabetes-part-3-of-3/>), Labiotech
- [Orbis and AlzeCure change CEOs; Simris hires another Heidelberg Pharma veteran](<https://european-biotechnology.com/latest-news/orbis-and-alzecure-change-ceos-simris-hires-another-heidelberg-pharma-veteran/>), European Biotechnology
- [Navigating geopolitical risks: Practical and legal mitigations for the pharmaceutical industry](<https://pharmaphorum.com/rd/navigating-geopolitical-risks-practical-and-legal-mitigations-pharmaceutical-industry>), pharmaphorum
- [Lilly's tirzepatide juggernaut is still gathering momentum](<https://pharmaphorum.com/news/lillys-tirzepatide-juggernaut-still-gathering-momentum>), pharmaphorum

## Sources

1. [Eli Lilly’s tirzepatide outperforms big pharma companies in Q3](<https://www.pharmaceutical-technology.com/news/eli-lillys-tirzepatide-outperforms-big-pharma-companies-in-q3/>), Pharmaceutical Technology, 2026-10-30
2. [AZ seeking $1.5bn in annual savings by end-2029](<https://pharmaphorum.com/news/az-seeking-15bn-annual-savings-end-2029>), pharmaphorum, 2026-10-30

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/eli-lillys-tirzepatide-outperforms-big-pharma-companies-in-q3/>
[2]: <https://pharmaphorum.com/news/az-seeking-15bn-annual-savings-end-2029>